Rhumbline Advisers Supernus Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 172,230 shares of SUPN stock, worth $8.27 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
172,230
Previous 165,323
4.18%
Holding current value
$8.27 Million
Previous $5.41 Million
0.26%
% of portfolio
0.0%
Previous 0.01%
Shares
33 transactions
Others Institutions Holding SUPN
# of Institutions
313Shares Held
61.7MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$499 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$298 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$231 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$145 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$133 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.57B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...